Boehringer Ingelheim's Phase III trials of survodutide, a glucagon/GLP-1 dual agonist, showed significant metabolic health improvements in people with obesity. The SYNCHRONIZE-1 trial reported up to 16.6% weight loss, 34% reduction in visceral fat, and 63% reduction in liver fat over 76 weeks, with minimal lean mass loss. The SYNCHRONIZE-MASLD trial showed liver fat normalization in 60% of participants with metabolic liver disease after 48 weeks. These results highlight survodutide's potential to target harmful fat and improve metabolic conditions linked to obesity, with further studies ongoing.
OpenAI is preparing its biggest upgrade yet, transforming ChatGPT into a superapp with multiple tools like coding and AI agents to better compete with Anthropic. This move aims to attract more corporate clients and increase revenue as OpenAI readies ...
Crédit Agricole S.A. announced it will repay its senior non-preferred bonds issued on June 3, 2021, totaling ¥84.2 billion JPY, on July 6, 2026. The repayment will be at 100% of the principal plus accrued interest up to the repayment date. This move ...
Crédit Agricole S.A. announced it will redeem all outstanding ¥84.2 billion Japanese Yen callable senior non-preferred bonds issued in June 2021 on July 6, 2026. The redemption will be at 100% of the principal amount plus accrued interest, ceasing bo...
Anthropic, an AI company backed by Amazon and Google, is preparing for a major IPO potentially valuing it near $1 trillion. Co-founder Jack Clark cautions that the AI industry currently has no mechanism to slow development, likening it to having a ga...
In 2009, Nvidia CEO Jensen Huang predicted GPUs would surpass CPUs in computing importance, a vision now expanding as Nvidia launches new chips combining Arm-based CPUs and advanced GPUs. The RTX Spark Superchip aims to improve laptop battery life an...
